GALT
Galectin Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$4.00-4.19%
Price as of Jul 20, 2026
GALT financials
Galectin Therapeutics Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $20.1M | $42.4M | $38.1M | $38.4M |
| Operating income | -$20.1M | -$42.4M | -$38.1M | -$38.4M |
| Net income | -$30.8M | -$47.0M | -$41.1M | -$38.8M |
| EBITDA | -$23.5M | -$41.5M | -$38.2M | -$37.7M |
| Basic EPS | $-0.48 | $-0.76 | $-0.74 | $-0.65 |
| Diluted EPS | $-0.48 | $-0.76 | $-0.74 | $-0.65 |
| Balance sheet | ||||
| Cash & equivalents | $17.7M | $15.1M | $25.7M | $18.6M |
| Total assets | $19.5M | $17.5M | $28.2M | $21.3M |
| Total liabilities | $145.7M | $120.6M | $88.4M | $53.5M |
| Stockholders’ equity | -$126.2M | -$103.1M | -$60.2M | -$32.2M |
| Total debt | $133.8M | $106.2M | $71.8M | $39.9M |
| Net debt | $116.0M | $91.1M | $46.1M | $21.3M |
| Cash flow | ||||
| Operating cash flow | -$23.9M | -$41.8M | -$33.0M | -$31.1M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$23.9M | -$41.8M | -$33.0M | -$31.1M |
| Dividends paid | $0.00 | -$91.0K | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |